(Alliance News) - PharmaNutra Spa's board of directors on Thursday approved the group's preliminary sales figures for fiscal year 2023, reporting consolidated net revenues of EUR100.2 million, up 21 percent from the full year 2022 when they were EUR82.7 million.

Revenues in the Italian market increased 15 percent to EUR68 million from EUR59.2 million in 2022 while overseas revenues grew 37 percent to EUR32.2 million from EUR23.5 million in 2022.

Roberto Lacorte, vice president of PharmaNutra, commented, "Reaching EUR100 million in sales is an excellent result that years ago we saw as something extremely ambitious, in perfect line with our way of working that from the very beginning has been characterized by ambition, passion and intuition. For PharmaNutra, this is not a milestone, but a very important intermediate step, to be celebrated, that makes us a reference point in the field of entrepreneurship and that is worth a lot in both emotional and concrete terms, because it means entering a new, increasingly relevant dimension. I would like to reiterate, however, that this is only a step of growth, because ahead of us we have other ambitious goals that we want to achieve with the same effectiveness and through the same path undertaken so far."

PharmaNutra closed Thursday in the red by 0.7 percent at EUR56.40 per share.

By Chiara Bruschi, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.